AAAAAA

   
Results: 1-8 |
Results: 8
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies
Authors: Bowcock, AM Shannon, W Du, FH Duncan, J Cao, K Aftergut, K Catier, J Fernandez-Vina, MA Menter, A
Citation: Am. Bowcock et al., Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies, HUM MOL GEN, 10(17), 2001, pp. 1793-1805
Cyclosporine and tacrolimus in dermatology
Authors: Cather, JC Abramovits, W Menter, A
Citation: Jc. Cather et al., Cyclosporine and tacrolimus in dermatology, DERM CLIN, 19(1), 2001, pp. 119
Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis
Authors: Lebwohl, M Drake, L Menter, A Koo, J Gottlieb, AB Zanolli, M Young, M McClelland, P
Citation: M. Lebwohl et al., Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis, J AM ACAD D, 45(4), 2001, pp. 544-553
The impact of psoriasis on quality of life - Results of a 1998 National Psoriasis Foundation Patient-Membership Survey
Authors: Krueger, G Koo, J Lebwohl, M Menter, A Stern, RS Rolstad, T
Citation: G. Krueger et al., The impact of psoriasis on quality of life - Results of a 1998 National Psoriasis Foundation Patient-Membership Survey, ARCH DERMAT, 137(3), 2001, pp. 280-284
Pharmacokinetics and safety of tazarotene
Authors: Menter, A
Citation: A. Menter, Pharmacokinetics and safety of tazarotene, J AM ACAD D, 43(2), 2000, pp. S31-S35
Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinicallysignificant improvement when treating psoriasis?
Authors: Krueger, GG Feldman, SR Camisa, C Duvic, M Elder, JT Gottlieb, AB Koo, J Krueger, JG Lebwohl, M Lowe, N Menter, A Morison, WL Prystowsky, JH Shupack, JL Taylor, JR Weinstein, GD Barton, TL Rolstad, T Day, RM
Citation: Gg. Krueger et al., Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinicallysignificant improvement when treating psoriasis?, J AM ACAD D, 43(2), 2000, pp. 281-285
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Authors: Abrams, JR Lebwohl, MG Guzzo, CA Jegasothy, BV Goldfarb, MT Goffe, BS Menter, A Lowe, NJ Krueger, G Brown, MJ Weiner, RS Birkhofer, MJ Warner, GL Berry, KK Linsley, PS Krueger, JG Ochs, HD Kelley, SL Kang, SW
Citation: Jr. Abrams et al., CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris, J CLIN INV, 103(9), 1999, pp. 1243-1252
Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis
Authors: Gollnick, H Menter, A
Citation: H. Gollnick et A. Menter, Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis, BR J DERM, 140, 1999, pp. 18-23
Risultati: 1-8 |